Table 4.

Univariate and multivariate analyses of overall survival in patients with cytogenetically normal AML, for the LSC- DNM gene-sets

Dataset	Variate model	Variates	HR	95% CI	p-value
GSE12417 (n = 242)	Univariate model	3 DNM fGSs vs. 4 control fGSs	0.53	0.35-0.79	0.0014**
		Age group, years (≥60 vs. <60)	1.63	1.18-2.26	0.0029**
	Multivariate model	3 DNM fGSs vs. 4 control fGSs	0.6	0.37-0.83	0.0038**
		Age group, years (≥60 vs. <60)	1.6	1.12-2.15	0.0083**
GSE14468 (n = 214)	Univariate model	3 DNM fGSs v.s 4 control fGSs	0.5	0.33-0.77	0.0012**
		KRAS mutaion vs. others	70.2	7.30-674.5	8.60E-13***
		ELN_risk (IntermediateI vs. Favorable)	1.8	1.27-2.62	0.00095***
		Age group, years (≥60 vs. <60)	1.4	0.89-2.18	0.15
		NPM1 mutation vs. others	0.8	0.57-1.12	0.19
		CEBPA mutation vs. others	0.7	0.42-1.22	0.22
		Gender	0.9	0.62-1.21	0.39
		BM Blast (>50 vs. <=50)	1.1	0.76-1.53	0.68
		NRAS mutation vs. others	1.0	0.60-1.81	0.90
	Multivariate model	3 DNM fGSs v.s 4 control fGSs	0.5	0.35-0.83	0.0047**
		KRAS mutaion vs. others	90.7	9.27-888.79	0.00011***
		ELN_risk (IntermediateI vs. Favorable)	1.7	1.19-2.48	0.0039**
TCGA (n = 91)	Univariate model	3 DNM fGSs vs. 4 control fGSs	0.4	0.19-0.67	8.23E-04***
		Age group, years (≥60 vs. <60)	2.5	1.58-4.09	6.53E-05***
		BM Blast (>50 vs. <=50)	0.6	0.33-1.09	0.09.
		Gender	0.7	0.46-1.16	0.18
	Multivariate model	3 DNM fGSs vs. 4 control fGSs	0.4	0.23-0.84	0.012*
		Age group, years (≥60 vs. <60)	2.1	1.32-3.47	0.0022**

Significance code: ‘.’:p < .1; ‘*’: p < .05; ‘**’p < .01; ‘***’p < .001.

Significant univariate tested factors (p < .05) are used for multivariate test. Boldface highlights the results of DMN fGSs.